Healthcare / BiotechnologyTaipei Exchange
$62.30
-0.90 (-1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $83.6M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.9B
P/E
25.6x
↑EV/EBITDA
17.3x
↑ROE
15.1%
↑Gross Margin
90.8%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+81.0%
FCF CAGR
+138.1%
FCF margin
46.1%
FCF / Net income
1.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $293.2M · net income $111.9M · FCF $135.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $293.2M | $293.2M | $286.4M | $130.6M | $49.5M |
| Net Income | $111.9M | $111.9M | $147.2M | $33.5M | $-5.2M |
| EBITDA | $156.0M | $156.0M | $187.4M | $55.6M | $11.2M |
| EPS | — | — | 3.20 | 0.74 | -0.14 |
| Gross Margin | 90.8% | 90.8% | 91.0% | 87.1% | 90.2% |
| Operating Margin | 40.2% | 40.2% | 54.4% | 21.0% | -18.1% |
| Net Margin | 38.2% | 38.2% | 51.4% | 25.6% | -10.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.06 | 0.15 | 0.22 |
| Current Ratio | 9.75 | 9.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $135.0M | $135.0M | $83.6M | $20.3M | $10.0M |
| Returns | |||||
| ROE | 15.1% | 15.1% | 23.7% | 7.1% | -1.6% |
| Valuation | |||||
| P/E | 25.64 | 25.64 | 21.59 | 83.78 | — |
| EV/EBITDA | 17.27 | 17.27 | 16.09 | 47.11 | — |
| P/B | 3.86 | 3.86 | 5.13 | 5.93 | — |
| Growth & Yield | |||||
| Revenue Growth | 2.4% | 2.4% | 119.4% | 163.9% | — |
| EPS Growth | — | — | 332.4% | 628.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.9%
Start / end P/E
n/dx → n/dx
EPS bridge
3.20 → n/d
Residual
-14.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.